AU6158096A - Spironolactone and angiotensin ii antagonist combination the rapy for treatment of congestive heart failure - Google Patents
Spironolactone and angiotensin ii antagonist combination the rapy for treatment of congestive heart failureInfo
- Publication number
- AU6158096A AU6158096A AU61580/96A AU6158096A AU6158096A AU 6158096 A AU6158096 A AU 6158096A AU 61580/96 A AU61580/96 A AU 61580/96A AU 6158096 A AU6158096 A AU 6158096A AU 6158096 A AU6158096 A AU 6158096A
- Authority
- AU
- Australia
- Prior art keywords
- angiotensin
- receptor antagonist
- spironolactone
- treatment
- heart failure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000002333 angiotensin II receptor antagonist Substances 0.000 title abstract 4
- 238000002648 combination therapy Methods 0.000 title abstract 3
- 229960002256 spironolactone Drugs 0.000 title abstract 3
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 title abstract 3
- 206010007559 Cardiac failure congestive Diseases 0.000 title abstract 2
- 206010019280 Heart failures Diseases 0.000 title abstract 2
- 229940123413 Angiotensin II antagonist Drugs 0.000 title 1
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 abstract 3
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 abstract 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 abstract 3
- 229940044551 receptor antagonist Drugs 0.000 abstract 3
- 239000002464 receptor antagonist Substances 0.000 abstract 3
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 abstract 2
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 abstract 1
- -1 3,5-dibutyl-1H-1,2,4-triazol-1-yl Chemical group 0.000 abstract 1
- 206010003445 Ascites Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 230000007882 cirrhosis Effects 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000001425 triazolyl group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48608995A | 1995-06-07 | 1995-06-07 | |
| US486089 | 1995-06-07 | ||
| PCT/US1996/009342 WO1996040258A2 (en) | 1995-06-07 | 1996-06-05 | Spironolactone and angiotensin ii antagonist combination therapy for treatment of congestive heart failure |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU42642/00A Division AU4264200A (en) | 1995-06-07 | 2000-06-23 | Spironolactone and angiotensin II antagonist combination therapy for treatment of congestive heart failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU6158096A true AU6158096A (en) | 1996-12-30 |
Family
ID=23930539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU61580/96A Abandoned AU6158096A (en) | 1995-06-07 | 1996-06-05 | Spironolactone and angiotensin ii antagonist combination the rapy for treatment of congestive heart failure |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20040102423A1 (https=) |
| EP (1) | EP0831911B1 (https=) |
| JP (1) | JPH11509838A (https=) |
| KR (1) | KR19990022723A (https=) |
| CN (1) | CN1192696A (https=) |
| AT (1) | ATE216261T1 (https=) |
| AU (1) | AU6158096A (https=) |
| BR (1) | BR9608505A (https=) |
| CA (1) | CA2224222A1 (https=) |
| CZ (1) | CZ291268B6 (https=) |
| DE (1) | DE69620756T2 (https=) |
| DK (1) | DK0831911T3 (https=) |
| ES (1) | ES2175098T3 (https=) |
| IL (1) | IL122246A (https=) |
| PT (1) | PT831911E (https=) |
| WO (1) | WO1996040258A2 (https=) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6306826B1 (en) | 1997-06-04 | 2001-10-23 | The Regents Of The University Of California | Treatment of heart failure with growth hormone |
| US6211217B1 (en) | 1999-03-16 | 2001-04-03 | Novartis Ag | Method for reducing pericardial fibrosis and adhesion formation |
| DK1216038T3 (da) | 1999-08-30 | 2005-12-27 | Sanofi Aventis Deutschland | Anvendelse af inhibitorer af reninangiotensinsystemet ved forebyggelsen af cardiovaskulære hændelser |
| WO2001060362A1 (fr) * | 2000-02-18 | 2001-08-23 | Takeda Chemical Industries, Ltd. | INHIBITEURS DE TNF-$g(a) |
| US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
| EP1465869B1 (en) | 2001-12-21 | 2013-05-15 | Exelixis Patent Company LLC | Modulators of lxr |
| DE10335027A1 (de) * | 2003-07-31 | 2005-02-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Angiotensin II Rezeptor Antagonisten |
| WO2005089380A2 (en) | 2004-03-16 | 2005-09-29 | The Regents Of The University Of California | Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids |
| US20050026844A1 (en) | 2003-04-03 | 2005-02-03 | Regents Of The University Of California | Inhibitors for the soluble epoxide hydrolase |
| JP2008517072A (ja) * | 2004-10-20 | 2008-05-22 | ザ レジェンツ オブ ザ ユニバーシティー オブ カリフォルニア | 可溶性エポキシド加水分解酵素の改良された阻害剤 |
| EP1831225A2 (en) * | 2004-11-19 | 2007-09-12 | The Regents of the University of California | Anti-inflammatory pyrazolopyrimidines |
| WO2007114926A2 (en) | 2006-04-04 | 2007-10-11 | The Regents Of The University Of California | Kinase antagonists |
| EP2051696A2 (en) * | 2006-08-18 | 2009-04-29 | Morton Grove Pharmaceuticals, Inc. | Stable liquid levetiracetam compositions and methods |
| GB2467670B (en) * | 2007-10-04 | 2012-08-01 | Intellikine Inc | Chemical entities and therapeutic uses thereof |
| MX2010007419A (es) * | 2008-01-04 | 2010-11-12 | Intellikine Inc | Ciertas entidades quimicas, composiciones y metodos. |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
| EP2252293B1 (en) * | 2008-03-14 | 2018-06-27 | Intellikine, LLC | Kinase inhibitors and methods of use |
| US20110224223A1 (en) * | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
| BRPI0915231A2 (pt) * | 2008-07-08 | 2018-06-12 | Intellikine Inc | compostos inibidores de quinase e métodos de uso |
| CA2738429C (en) | 2008-09-26 | 2016-10-25 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
| EP2358720B1 (en) | 2008-10-16 | 2016-03-02 | The Regents of The University of California | Fused ring heteroaryl kinase inhibitors |
| US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
| CN102369205B (zh) | 2009-01-30 | 2014-10-29 | 武田药品工业株式会社 | 稠环化合物和其用途 |
| JP5789252B2 (ja) | 2009-05-07 | 2015-10-07 | インテリカイン， エルエルシー | 複素環式化合物およびその使用 |
| WO2011047384A2 (en) | 2009-10-16 | 2011-04-21 | The Regents Of The University Of California | Methods of inhibiting ire1 |
| CA2799579A1 (en) | 2010-05-21 | 2011-11-24 | Intellikine, Inc. | Chemical compounds, compositions and methods for kinase modulation |
| JP2013545749A (ja) | 2010-11-10 | 2013-12-26 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | 複素環化合物及びその使用 |
| ES2637113T3 (es) | 2011-01-10 | 2017-10-10 | Infinity Pharmaceuticals, Inc. | Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas |
| CN107899012A (zh) | 2011-01-11 | 2018-04-13 | 戴麦里克斯生物科学有限公司 | 联合疗法 |
| US9295673B2 (en) | 2011-02-23 | 2016-03-29 | Intellikine Llc | Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof |
| CN102816126A (zh) * | 2011-06-07 | 2012-12-12 | 中国药科大学 | 具有心血管活性的胺磺酰芳基取代的三氮唑类衍生物、其制备方法及用途 |
| AR088218A1 (es) | 2011-07-19 | 2014-05-21 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos utiles como inhibidores de pi3k |
| HK1198443A1 (en) | 2011-07-19 | 2015-04-24 | 无限药品股份有限公司 | Heterocyclic compounds and uses thereof |
| MX2014002542A (es) | 2011-08-29 | 2014-07-09 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos y usos de los mismos. |
| CA2846496C (en) | 2011-09-02 | 2020-07-14 | The Regents Of The University Of California | Substituted pyrazolo[3,4-d]pyrimidines and uses thereof |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| JP2015532287A (ja) | 2012-09-26 | 2015-11-09 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | Ｉｒｅ１の調節 |
| AU2013337717B2 (en) | 2012-11-01 | 2018-10-25 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using PI3 kinase isoform modulators |
| US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| PT3052485T (pt) | 2013-10-04 | 2021-10-22 | Infinity Pharmaceuticals Inc | Compostos heterocíclicos e suas utilizações |
| MX382033B (es) | 2014-03-19 | 2025-03-13 | Infinity Pharmaceuticals Inc | Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma. |
| WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| WO2016141182A1 (en) | 2015-03-03 | 2016-09-09 | Yee Richard W | Compositions and methods for treating ocular diseases |
| WO2017048702A1 (en) | 2015-09-14 | 2017-03-23 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
| WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| SG11201811237WA (en) | 2016-06-24 | 2019-01-30 | Infinity Pharmaceuticals Inc | Combination therapies |
| ES2984389T3 (es) | 2016-06-29 | 2024-10-29 | Univ Montreal | Heterociclos de biarilmetilo |
| CA3121202A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3257390A (en) * | 1963-06-12 | 1966-06-21 | Merck & Co Inc | Ring a unsaturated 21-hydroxy-3-oxo-17alpha-pregnane-17-carboxylic acid lactone diuretic agents |
| DE2652761C2 (de) * | 1976-11-16 | 1985-11-21 | Schering AG, 1000 Berlin und 4709 Bergkamen | 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
| DE3506100A1 (de) * | 1985-02-18 | 1986-08-21 | Schering AG, 1000 Berlin und 4709 Bergkamen | 1(alpha).7(alpha)-dithiosubstituierte spirolactone, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| JPH05504969A (ja) * | 1990-02-13 | 1993-07-29 | メルク・エンド・カムパニー・インコーポレーテツド | 置換ベンジル要素を含有するアンギオテンシン２アンタゴニスト類 |
| WO1991015206A1 (en) * | 1990-04-05 | 1991-10-17 | E.I. Du Pont De Nemours And Company | Treatment of glaucoma and ocular hypertension with imidazole angiotensin-ii receptor antagonists |
| CA2053148A1 (en) * | 1990-10-16 | 1992-04-17 | Karnail Atwal | Dihydropyrimidine derivatives |
| US5049565A (en) * | 1990-12-07 | 1991-09-17 | Merck & Co., Inc. | Microbial transformation process for preparing anti-hypertensive products |
| CA2109524A1 (en) * | 1991-05-10 | 1992-11-11 | Prasun K. Chakravarty | Acidic aralkyl triazole derivatives active as angiotensin ii antagonists |
| US5529992A (en) * | 1992-04-21 | 1996-06-25 | Curators Of The University Of Missouri | Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors |
| US5264447A (en) * | 1992-09-01 | 1993-11-23 | Merck & Co., Inc. | Angiotensin II antagonist |
| AU5449194A (en) * | 1992-10-26 | 1994-05-24 | Merck & Co., Inc. | Combinations of angiotensin-ii receptor antagonists and diuretics |
| CA2125251C (en) * | 1993-06-07 | 2005-04-26 | Yoshiyuki Inada | A pharmaceutical composition for angiotensin ii-mediated diseases |
-
1996
- 1996-06-05 KR KR1019970709165A patent/KR19990022723A/ko not_active Ceased
- 1996-06-05 EP EP96919173A patent/EP0831911B1/en not_active Expired - Lifetime
- 1996-06-05 CN CN96196086A patent/CN1192696A/zh active Pending
- 1996-06-05 IL IL12224696A patent/IL122246A/en not_active IP Right Cessation
- 1996-06-05 DE DE69620756T patent/DE69620756T2/de not_active Expired - Fee Related
- 1996-06-05 AT AT96919173T patent/ATE216261T1/de not_active IP Right Cessation
- 1996-06-05 JP JP9501683A patent/JPH11509838A/ja not_active Abandoned
- 1996-06-05 WO PCT/US1996/009342 patent/WO1996040258A2/en not_active Ceased
- 1996-06-05 PT PT96919173T patent/PT831911E/pt unknown
- 1996-06-05 ES ES96919173T patent/ES2175098T3/es not_active Expired - Lifetime
- 1996-06-05 CA CA002224222A patent/CA2224222A1/en not_active Abandoned
- 1996-06-05 BR BR9608505A patent/BR9608505A/pt not_active Application Discontinuation
- 1996-06-05 AU AU61580/96A patent/AU6158096A/en not_active Abandoned
- 1996-06-05 DK DK96919173T patent/DK0831911T3/da active
- 1996-06-05 CZ CZ19973848A patent/CZ291268B6/cs not_active IP Right Cessation
-
2002
- 2002-10-15 US US10/271,362 patent/US20040102423A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR19990022723A (ko) | 1999-03-25 |
| CZ291268B6 (cs) | 2003-01-15 |
| ES2175098T3 (es) | 2002-11-16 |
| US20040102423A1 (en) | 2004-05-27 |
| IL122246A (en) | 2004-06-01 |
| WO1996040258A3 (en) | 1997-01-23 |
| EP0831911B1 (en) | 2002-04-17 |
| CA2224222A1 (en) | 1996-12-19 |
| JPH11509838A (ja) | 1999-08-31 |
| DK0831911T3 (da) | 2002-07-22 |
| IL122246A0 (en) | 1998-04-05 |
| DE69620756T2 (de) | 2002-11-14 |
| CZ384897A3 (cs) | 1998-05-13 |
| PT831911E (pt) | 2002-09-30 |
| BR9608505A (pt) | 1999-07-06 |
| WO1996040258A2 (en) | 1996-12-19 |
| EP0831911A2 (en) | 1998-04-01 |
| CN1192696A (zh) | 1998-09-09 |
| DE69620756D1 (de) | 2002-05-23 |
| ATE216261T1 (de) | 2002-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU6158096A (en) | Spironolactone and angiotensin ii antagonist combination the rapy for treatment of congestive heart failure | |
| WO1996040255A3 (en) | Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldosterone antagonist | |
| NZ310730A (en) | Epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of congestive heart failure | |
| IE902139L (en) | Imidazolyl alkenoic acids | |
| AU640417B2 (en) | Substituted 5-((tetrazolyl)alkenyl)imidazoles | |
| NZ330889A (en) | Cycloalkyl substituted imidazoles and their use in treating CSB/RK/p38 kinase mediated diseases | |
| AU8844491A (en) | Renal-selective biphenylalkyl 1h-substituted-1,2,4-triazole angiotensin ii antagonists for treatment of hypertension | |
| IE902140L (en) | Imidazolyl alkenoic acids | |
| EP0437103A3 (en) | Substituted 5-(alkyl)carboxamide imidazoles | |
| WO2002009760A3 (en) | Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure | |
| WO1991000281A3 (en) | Fused-ring aryl substituted imidazoles | |
| EP0323841A3 (en) | Substituted pyrrole, pyrazole and triazole angiotensin ii antagonists | |
| PT85312A (en) | Process for the preparation of angiotension ii receptor blocking imidazoles and of pharmaceutical | |
| CA2105867A1 (en) | Novel imidazole derivatives, their preparation and therapeutic applications | |
| CA2371012A1 (en) | 4-(1h-pyrrol-1-yl) imidazoles | |
| RO118870B1 (ro) | Monometansulfonat de acid (e)-alfa-[2-n-butil-1-[(4-carboxifenil)metil]-1h-imidazol-5-il]metilen-2-tiofenpropionic, procedee de preparare şi compoziţii farmaceutice | |
| EP0726072A3 (en) | Composition for the treatment of hypertension and congestive heart failure, containing an angiotensin II antagonist and an endopeptidase inhibitor | |
| AU641952B2 (en) | Substituted N-(imidazolyl)alkyl alanine derivatives | |
| AU8534291A (en) | Renal-selective angiotensin ii antagonists for treatment of hypertension | |
| CA2072233A1 (en) | Triazolopyrimidine derivatives which are angiotensin ii receptor antagonists; processes for preparing them and pharmaceutical compositions containing them | |
| AU1582097A (en) | 1-(n'-(arylalkylaminoalkyl)) aminoisoindoles; dopamine receptor subtype specificligands | |
| MX9709976A (es) | Terapia de combinacion con espironolactona y antagonista de angiotensina ii para el tratamiento de fallas cardiacas congestivas. | |
| AU3635793A (en) | Pyrazolopyrimidin derivatives as angiotensin II receptor antagonists | |
| CA2182477A1 (en) | Pyridyl Imidazole Derivatives and Processes for the Preparation Thereof | |
| MX9709978A (es) | Terapia de combinacion de antagonista de aldosterona epoxi-esteroidal y antagonista de angiotensina ii para tratamiento de insuficiencia cardiaca congestiva. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |